Charles River Laboratories International’s (CRL) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Charles River Laboratories International (NYSE:CRL) in a research report released on Tuesday,Benzinga reports.

A number of other brokerages also recently issued reports on CRL. Evercore ISI boosted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. UBS Group upped their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. Finally, Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Stock Down 4.8 %

CRL opened at $165.60 on Tuesday. The firm’s 50 day simple moving average is $192.56 and its two-hundred day simple moving average is $198.95. The company has a market capitalization of $8.47 billion, a PE ratio of 20.73, a PEG ratio of 6.62 and a beta of 1.38. Charles River Laboratories International has a 1-year low of $160.85 and a 1-year high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.72 EPS. As a group, equities analysts forecast that Charles River Laboratories International will post 10.18 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of Charles River Laboratories International

A number of institutional investors have recently bought and sold shares of the stock. Mitchell & Pahl Private Wealth LLC raised its position in Charles River Laboratories International by 8.8% in the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 3,603 shares of the medical research company’s stock worth $665,000 after purchasing an additional 292 shares during the period. Kera Capital Partners Inc. bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $246,000. Pinnacle Bancorp Inc. boosted its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Fiduciary Financial Group LLC grew its stake in Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the last quarter. Finally, Czech National Bank grew its position in shares of Charles River Laboratories International by 5.4% in the 4th quarter. Czech National Bank now owns 11,088 shares of the medical research company’s stock worth $2,047,000 after buying an additional 571 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).